|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0030705,
umls-concept:C0055598,
umls-concept:C0059985,
umls-concept:C0332152,
umls-concept:C0332293,
umls-concept:C0332306,
umls-concept:C0334634,
umls-concept:C0393022,
umls-concept:C0871261,
umls-concept:C1282910,
umls-concept:C1413947,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C2911692,
umls-concept:C2926735
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-7-15
|
|
pubmed:abstractText |
Sixteen patients with relapsed mantle-cell lymphoma (MCL) were treated with the combination of fludarabine and cyclophosphamide (FC) with or without rituximab. All patients had received prior CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy, with a response rate of 63.5% (25% complete response), and a median duration of response of 10 months (range 1-32 months). Subsequent treatment with FC +/- rituximab produced a response rate of 75% with a higher complete response rate (56% P = 0.07 vs. CHOP), and a median duration of response of 11 months (4-25+ months). This study demonstrates that FC is a highly active regimen in patients relapsing following CHOP chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
549-52
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16019483-Adult,
pubmed-meshheading:16019483-Aged,
pubmed-meshheading:16019483-Antibodies, Monoclonal,
pubmed-meshheading:16019483-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16019483-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16019483-Cyclophosphamide,
pubmed-meshheading:16019483-Disease-Free Survival,
pubmed-meshheading:16019483-Doxorubicin,
pubmed-meshheading:16019483-Humans,
pubmed-meshheading:16019483-Lymphoma, Mantle-Cell,
pubmed-meshheading:16019483-Middle Aged,
pubmed-meshheading:16019483-Prednisone,
pubmed-meshheading:16019483-Recurrence,
pubmed-meshheading:16019483-Remission Induction,
pubmed-meshheading:16019483-Retrospective Studies,
pubmed-meshheading:16019483-Treatment Outcome,
pubmed-meshheading:16019483-Vidarabine,
pubmed-meshheading:16019483-Vincristine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
|
|
pubmed:affiliation |
Department of Haematology, Derriford Hospital, Plymouth, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
